Report Title:
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H1 2018 Published On: January 2018
Category: Life Sciences
Pages: 65
Report Overview: Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 Pipeline Review, H1 2018 Summary Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Pipeline Review, H1 2018, outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 Induced myeloid leukemia cell differentiation protein Mcl1 also known as Bcl2like protein 3 or bcl2related protein EATS/Mcl1 is a protein encoded by the MCL1 gene. It is involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. It mediates its effects by interactions with a number of other regulators of apoptosis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Multiple Myeloma Kahler Disease, Breast Cancer, Chronic Lymphocytic Leukemia CLL, Pancreatic Cancer, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Colorectal Cancer, Diffuse Large BCell Lymphoma, Glioblastoma Multiforme GBM, Head And Neck Cancer, Hematological Tumor, Malignant Mesothelioma, MethicillinResistant Staphylococcus aureus MRSA Infections, Myelodysplastic Syndrome, NonHodgkin Lymphoma, Ovarian Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Solid Tumor and TCell Lymphomas. Furthermore, this report also
24marketreports | International +1 646 781 7170 | www.24marketreports.com
reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 targeted therapeutics and enlists all their major and minor projects The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 targeted therapeutics Reasons to buy Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic Develop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 development landscape Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Table of Contents: Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 Overview Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 Companies Involved in Therapeutics Development AbbVie Inc Amgen Inc AstraZeneca Plc Complix NV Les Laboratoires Servier SAS Takeda Pharmaceutical Co Ltd Warp Drive Bio Inc Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 Drug Profiles AMG176 Drug Profile Product Description Mechanism Of Action R&D Progress AT101 Drug Profile Product Description Mechanism Of Action R&D Progress AZD5991 Drug Profile Product Description Mechanism Of Action R&D Progress
24marketreports | International +1 646 781 7170 | www.24marketreports.com
FL118 Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Proteins to Inhibit MCL1 for Oncology Drug Profile Product Description Mechanism Of Action R&D Progress S63845 Drug Profile Product Description Mechanism Of Action R&D Progress S64315 Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Mcl1 and BclxL for Oncology Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Mcl1 and BclxL for Oncology and MRSA Infections Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit MCL1 for Breast Cancer Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit MCL1 for Oncology Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit MCL1 for Oncology Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit MCL1 for Multiple Myeloma Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit MCL1 for Oncology Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit MCL1 for Oncology Drug Profile Product Description
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Mechanism Of Action R&D Progress Synthetic Peptides to Inhibit MCL1 for Oncology Drug Profile Product Description Mechanism Of Action R&D Progress UMI77 Drug Profile Product Description Mechanism Of Action R&D Progress Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 Dormant Products Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1 Product Development Milestones Featured News & Press Releases Dec 14, 2017: Complix receives â‚Ź0.5 million grant to further develop its pipeline of proprietary Cell Penetrating Alphabodies against intracellular cancer targets Aug 03, 2017: Targeting Cancers Achilles Heel To Improve Breast Cancer Treatment Mar 31, 2017: Amgen To Highlight New Preclinical Data At The American Association For Cancer Research AACR Annual Meeting Oct 20, 2016: New compound shows promise in treating multiple human cancers Oct 13, 2016: Ascentage Pharma takes a leading position in novel drug development targeting dual pathways of apoptosis and autophagy Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, LowToxicity Anticancer Agent Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT101 At 2009 ASCO Annual Meeting Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT101 At 2009 Asco Annual Meeting Appendix Methodology Coverage Secondary Research
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Primary Research Expert Panel Validation Contact Us Disclaimer
Get More Information about the Report: Report URL: https://www.24marketreports.com/life-sciences/induced-myeloid-leukemia-cell-differentiation-p rotein-mcl-1-bcl-2-like-protein-3-or-bcl-2-related-protein-eatmcl1-or-bcl2l3-or-mcl1pipelinereview-h1-2018-market-38 To get Report Sample: https://www.24marketreports.com/request-sample/induced-myeloid-leukemia-cell-differentiatio n-protein-mcl-1-bcl-2-like-protein-3-or-bcl-2-related-protein-eatmcl1-or-bcl2l3-or-mcl1pipelinereview-h1-2018-market-38
24marketreports | International +1 646 781 7170 | www.24marketreports.com